ID   VMM5A
AC   CVCL_A740
SY   VMM-5A; VMM5
DR   ATCC; CRL-3226
DR   cancercelllines; CVCL_A740
DR   Cosmic; 890886
DR   GEO; GSM1672036
DR   GEO; GSM1672041
DR   GEO; GSM1672053
DR   GEO; GSM1672068
DR   GEO; GSM1672080
DR   GEO; GSM1672099
DR   GEO; GSM1672107
DR   GEO; GSM1672112
DR   GEO; GSM1672125
DR   Wikidata; Q54993271
RX   PubMed=7681084;
RX   PubMed=10752474;
RX   PubMed=14871852;
RX   PubMed=15905528;
RX   PubMed=20856146;
RX   PubMed=21654344;
RX   PubMed=26405815;
RX   PubMed=26673621;
CC   Population: Caucasian.
CC   HLA typing: A*02:01; B*39 (PubMed=10752474).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Arg173His (c.518G>A); ClinVar=VCV000376032; Zygosity=Unspecified (ATCC=CRL-3226).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): ATCC=CRL-3226
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 12
ST   D5S818: 9
ST   D7S820: 9,10
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_S584 ! VMM5B
SX   Male
AG   81Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 17
//
RX   PubMed=7681084; DOI=10.4049/jimmunol.150.7.2955;
RA   Slingluff C.L. Jr., Cox A.L., Henderson R.A., Hunt D.F.,
RA   Engelhard V.H.;
RT   "Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic
RT   T lymphocytes is mediated by at least six shared peptide epitopes.";
RL   J. Immunol. 150:2955-2963(1993).
//
RX   PubMed=10752474; DOI=10.1007/s002620050015; PMCID=PMC11037162;
RA   Slingluff C.L. Jr., Colella T.A., Thompson L., Graham D.D.,
RA   Skipper J.C.A., Caldwell J., Brinckerhoff L., Kittlesen D.J.,
RA   Deacon D.H., Oei C., Harthun N.L., Huczko E.L., Hunt D.F.,
RA   Darrow T.L., Engelhard V.H.;
RT   "Melanomas with concordant loss of multiple melanocytic
RT   differentiation proteins: immune escape that may be overcome by
RT   targeting unique or undefined antigens.";
RL   Cancer Immunol. Immunother. 48:661-672(2000).
//
RX   PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209;
RA   Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J.,
RA   Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.;
RT   "Identification of novel and widely expressed cancer/testis gene
RT   isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to
RT   melanoma.";
RL   Cancer Res. 64:1157-1163(2004).
//
RX   PubMed=15905528; DOI=10.4049/jimmunol.174.11.6863;
RA   Yamshchikov G.V., Mullins D.W., Chang C.-C., Ogino T., Thompson L.,
RA   Presley J., Galavotti H., Aquila W., Deacon D.H., Ross W.,
RA   Patterson J.W., Engelhard V.H., Ferrone S., Slingluff C.L. Jr.;
RT   "Sequential immune escape and shifting of T cell responses in a
RT   long-term survivor of melanoma.";
RL   J. Immunol. 174:6863-6871(2005).
//
RX   PubMed=20856146; DOI=10.1097/CMR.0b013e32833fafb4; PMCID=PMC3229868;
RA   Mikesh L.M., Kumar M., Erdag G., Hogan K.T., Molhoek K.R., Mayo M.W.,
RA   Slingluff C.L. Jr.;
RT   "Evaluation of molecular markers of mesenchymal phenotype in
RT   melanoma.";
RL   Melanoma Res. 20:485-495(2010).
//
RX   PubMed=21654344; DOI=10.1097/CMR.0b013e328343a1d6; PMCID=PMC3131461;
RA   Molhoek K.R., Shada A.L., Smolkin M., Chowbina S., Papin J.,
RA   Brautigan D.L., Slingluff C.L. Jr.;
RT   "Comprehensive analysis of receptor tyrosine kinase activation in
RT   human melanomas reveals autocrine signaling through IGF-1R.";
RL   Melanoma Res. 21:274-284(2011).
//
RX   PubMed=26405815; DOI=10.1371/journal.pone.0138210; PMCID=PMC4583389;
RA   Capaldo B.J., Roller D.G., Axelrod M.J., Koeppel A.F., Petricoin E.F. 3rd,
RA   Slingluff C.L. Jr., Weber M.J., Mackey A.J., Gioeli D., Bekiranov S.;
RT   "Systems analysis of adaptive responses to MAP kinase pathway blockade
RT   in BRAF mutant melanoma.";
RL   PLoS ONE 10:E0138210-E0138210(2015).
//
RX   PubMed=26673621; DOI=10.18632/oncotarget.6548; PMCID=PMC4823068;
RA   Roller D.G., Capaldo B.J., Bekiranov S., Mackey A.J., Conaway M.R.,
RA   Petricoin E.F. 3rd, Gioeli D., Weber M.J.;
RT   "Combinatorial drug screening and molecular profiling reveal diverse
RT   mechanisms of intrinsic and adaptive resistance to BRAF inhibition in
RT   V600E BRAF mutant melanomas.";
RL   Oncotarget 7:2734-2753(2016).
//